Apalutamide-induced severe interstitial lung disease: A report of two cases from Japan.

  title={Apalutamide-induced severe interstitial lung disease: A report of two cases from Japan.},
  author={Hiroshi Kobe and Ryo Tachikawa and Yoshitsugu Masuno and Atsushi Matsunashi and Shiori Murata and Hiroki Hagimoto and Keisuke Tomii},
  journal={Respiratory investigation},
3 Citations

Interstitial lung disease induced by apalutamide therapy for castration‐resistant prostate cancer: A report of a rare case

Apalutamide is a new second‐generation anti‐androgen agent approved in 2019 for the treatment of metastatic, castration‐sensitive, and non‐metastatic, castration‐resistant prostate cancer. We herein

A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease

A comprehensive overview of the use of antibodies in the treatment of infectious disease and cancer patients is provided and discussions of their mechanisms and history are discussed.


  • Biology, Chemistry
    Reactions Weekly
  • 2022
A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. Apalutamide binds to AR in target tissues thereby preventing androgen-induced receptor activation and